Clinical trials: CKD Stage 5
CKD Anemia
A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants with chronic kidney disease and not on dialysis.
- Trial name
- NCT01750190
- Testing
- Roxadustat
- Where
- 145 sites in United States, Argentina and 14 more
- Volunteers
- 922 people
- Sponsor
- Kyntra Bio
End Stage Kidney Disease
Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
Patients on haemodialysis are at higher risk of getting a severe form of COVID-19 if they become infected. Vaccinations are soon to arrive and offer great hope of controlling the current pandemic.
- Trial name
- NCT04815850
- Where
- United Kingdom
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Leicester
End Stage Renal Disease (ESRD), Diabetes
Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
Primary Objective: To demonstrate that use of glucose sparing prescriptions, Dianeal, Extraneal, Nutrineal (D-E-N) versus Dianeal only, in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) patients…
- Conditions
- End Stage Renal Disease (ESRD), Diabetes, CAPD
- Trial name
- EDEN (NCT01219959)
- Testing
- Dianeal, Dianeal, Extraneal, Nutrineal
- Where
- 16 sites in Colombia
- Volunteers
- 71 people
- Sponsor
- Vantive Health LLC
Anemia in Incident Dialysis Patients
Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants who have just begun dialysis treatment for ESRD.
- Trial name
- Himalayas (NCT02052310)
- Testing
- Roxadustat, Epoetin Alfa
- Where
- 113 sites in United States, Argentina and 13 more
- Volunteers
- 1,043 people
- Sponsor
- Kyntra Bio
End Stage Renal Disease (ESRD)
Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal
To determine the safety and efficacy of a new formulation of Myfortic in combination with tacrolimus and thymoglobulin.
- Trial name
- NCT00374803
- Testing
- Mycophenolic Acid (Myfortic)
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Cincinnati
Acute Kidney Injury, End-stage Renal Disease
Hemodynamic Effects of Blood Flow Variation in Continuous Renal Replacement Therapy
Purpose of this study is to evaluate the short-term hemodynamic effects of changes in blood flow rates in critically ill patients receiving continuous renal replacement therapy.
- Trial name
- NCT03078504
- Testing
- continuous renal replacement therapy using System One (TM) setup (Nxstage)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- St. Louis University
Continuous Ambulatory Peritoneal Dialysis, End Stage Renal Disease
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
The objective of this study is to characterize the pharmacokinetic profile of ertapenem during continuous ambulatory peritoneal dialysis (CAPD).
- Trial name
- NCT00939952
- Testing
- ertapenem
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Albany College of Pharmacy and Health Sciences
End Stage Renal Disease, AV Fistula
Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
A prospective single-arm well-controlled study to evaluate the safety and effectiveness of a less invasive means of establishing vascular access to facilitate dialysis in patients with end stage renal disease.
- Conditions
- End Stage Renal Disease, AV Fistula, Fistula, End Stage Kidney Disease
- Trial name
- NCT02363972
- Testing
- Ellipsys Vascular Access Catheter
- Where
- 5 sites in United States
- Volunteers
- 103 people
- Sponsor
- Medtronic Endovascular
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
End Stage Renal Disease (ESRD)
A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients
The aim of the study is to confirm the safety and clinical effectiveness of Nipro ELISIO-15H and to compare its performance characteristics and hemocompatibility with those of the commercially available dialyzers in U.S.A.…
- Trial name
- NCT02433210
- Testing
- ELISIO-15H, Revaclear, Optiflux
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Missouri-Columbia
End Stage Renal Disease
Reveal LINQ™ Evaluation of Fluid
The purpose of this study is to investigate the use of subcutaneous impedance measured with an implanted Medtronic Reveal LINQ™ insertable cardiac monitor for use as a fluid status monitor in hemodialysis patients.
- Trial name
- REEF (NCT02275923)
- Testing
- Reveal LINQ™ Insertable Cardiac Monitor
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
End Stage Renal Disease on Dialysis
Motivational Strategies To Empower African Americans To Improve Dialysis Adherence
This study addresses the need to rigorously advance the science and understanding of the development, feasibility, acceptability and adoption of novel culturally-sensitive motivational strategies to improve dialysis treatment…
- Trial name
- MoVE (NCT05003115)
- Testing
- Motivational interviewing
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt University Medical Center
End-Stage Renal Disease
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.
- Trial name
- SPin-D (NCT02285920)
- Testing
- Spironolactone
- Where
- 4 sites in United States
- Volunteers
- 129 people
- Sponsor
- University of Pennsylvania
Kidney Diseases, End Stage Renal Disease
Ixazomib for Desensitization
The purpose of this research study is to find out how well ixazomib (the study drug) works to desensitize highly sensitized kidney transplant recipients.
- Trial name
- IXADES (NCT03213158)
- Testing
- Ixazomib Oral Capsule
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Wisconsin, Madison
End Stage Renal Disease
SPIRIT for Persons With Dementia and Complex Multimorbidity
In this study, 30 patient and caregiver dyads will be randomized to receive the SPIRIT-dementia intervention or usual care. Participants will be follow-up with 2-3 days after the intervention to evaluate the impact of SPIRIT on…
- Trial name
- NCT04108000
- Testing
- SPIRIT-Dementia, Usual Care
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Emory University
End Stage Renal Disease
Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access
This study is a prospective, non-randomized, multi-center evaluation of the performance of the GORE® ACUSEAL Vascular Graft. The study will enroll patients with End-Stage Renal Disease (ESRD), who are either currently receiving…
- Trial name
- ACUSEAL (NCT01173718)
- Testing
- GORE® ACUSEAL Vascular Graft
- Volunteers
- 138 people
- Sponsor
- W.L.Gore & Associates
End Stage Renal Disease
Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR Compared to the Nipro ELISIO-15H
The aim of the study is to identify hepatic enzyme and estrogen-dependent biochemical changes that occur when dialysis patients are treated with dialyzers known to leach BPA (Bisphenol-A) into the blood, such as the commercially…
- Trial name
- bisphenol-A (NCT02627118)
- Testing
- FRESENIUS 160NR, NIPRO ELISIO-15H
- Volunteers
- 10 people
- Sponsor
- UConn Health
Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis)
Blood Pressure Lowering in Dialysis (BOLD) Trial
Blood pressure may be one of the most important modifiable risk factors for cardiovascular disease in patients with end-stage-renal-disease undergoing maintenance hemodialysis.
- Conditions
- Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis), Chronic Kidney Diseases, Chronic Kidney Disease Stage 5
- Trial name
- BOLD (NCT03459807)
- Testing
- Anti-Hypertensive medications, Dry Weight Adjustment
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
End-Stage Renal Disease, Type 2 Diabetes
Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)
The study is conducted to assess the efficacy of real-time CGM data in preventing hypoglycemia in patients with type 2 diabetes and end-stage kidney disease (ESKD), treated with insulin therapy and receiving hemodialysis.
- Trial name
- NCT04473430
- Testing
- Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Emory University
Cardiovascular Diseases, Cardiovascular Abnormalities
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease
- Trial name
- NCT02966028
- Testing
- SNF472
- Where
- 75 sites in United States, Spain and 1 more
- Volunteers
- 274 people
- Sponsor
- Sanifit Therapeutics S. A.